CardiacAssist, Inc., a Pittsburgh-based company has announced (.pdf) “the completion of the 500th worldwide procedure to help heart failure patients survive heart attacks, high-risk procedures and other cardiac interventions without undergoing major surgery.” The company is talking about the implantation of its TandemHeart PTVA System, a percutaneous left ventricular assist device (LVAD) with FDA 510(k) clearance for short-term use. Unlike other LVADs, the system can be inserted either by cardiovascular surgeons in the OR or by cardiologists in the cardiac catheterization lab.
And now about the technology:
The TandemHeart PTVA System is comprised of three sub-systems.
· The TandemHeart System Pump provides the circulating power to pull oxygenated blood from the left atrium and to return it to the systemic arterial circulation.
· By way of two percutaneous access points in the patient’s groin, the TandemHeart Cannula Family connects the pump to the body.
· The TandemHeart PTVA System Controller provides operating power to the pump, provides a controlled flow of lubricant to the pump, and also provides automatic system monitoring and alarms indicating conditions that require attention.